MAX
Company Analysis Celyad Oncology SA
1. Summary
Advantages
- The company's current efficiency (ROE=118.66%) is higher than the sector average (ROE=7.75%)
Disadvantages
- Price (0.35 $) is higher than fair price (0.35 $)
- Dividends (0%) are below the sector average (592.72%).
- The stock's return over the last year (-30%) is lower than the sector average (-5.13%).
- Current debt level 176.63% has increased over 5 years from 5.51%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Celyad Oncology SA | Index | ||
|---|---|---|---|
| 7 days | 0% | 14.3% | -1.3% |
| 90 days | 133.3% | -0.7% | -2.3% |
| 1 year | -30% | -5.1% | 12.1% |
CLYYF vs Sector: Celyad Oncology SA has significantly underperformed the "" sector by -24.87% over the past year.
CLYYF vs Market: Celyad Oncology SA has significantly underperformed the market by -42.13% over the past year.
Slightly volatile price: CLYYF is more volatile than the rest of the market on "USA Stocks" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: CLYYF with weekly volatility of -0.58% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (0.35 $) is higher than the fair price (0.35 $).
Price is higher than fair: The current price (0.35 $) is 0% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-2.92) is lower than that of the sector as a whole (227.7).
P/E vs Market: The company's P/E (-2.92) is lower than that of the market as a whole (134.59).
5.3. P/BV
P/BV vs Sector: The company's P/BV (-0.63) is lower than that of the sector as a whole (3.31).
P/BV vs Market: The company's P/BV (-0.63) is lower than that of the market as a whole (2.76).
5.5. P/S
P/S vs Sector: The company's P/S indicator (54.57) is higher than that of the sector as a whole (12.74).
P/S vs Market: The company's P/S indicator (54.57) is higher than that of the market as a whole (5.17).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.36) is higher than that of the sector as a whole (-9.09).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.36) is lower than that of the market as a whole (7.87).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -15.61% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-15.61%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-409.96%).
6.4. ROE
ROE vs Sector: The company's ROE (118.66%) is higher than that of the sector as a whole (7.75%).
ROE vs Market: The company's ROE (118.66%) is lower than that of the market as a whole (183.1%).
6.6. ROA
ROA vs Sector: The company's ROA (-44.44%) is lower than that of the sector as a whole (-0.56%).
ROA vs Market: The company's ROA (-44.44%) is lower than that of the market as a whole (164.88%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (8.35%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '592.72%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
